Anthony Rosenzweig, MD
Anthony Rosenzweig

Education and Training

Anthony Rosenzweig, MD, graduated from Harvard College, where he majored in biochemistry and molecular biology. He received his medical degree from Harvard Medical School and completed his residency in internal medicine and fellowship in cardiovascular medicine at the Massachusetts General Hospital (MGH). Additional research training included a one-year predoctoral fellowship in neurosciences at the University of Pennsylvania and postdoctoral training in the laboratories of Drs. Jonathan and Christine Seidman, as well as Dr. Michael Gimbrone, all at Harvard Medical School.


Dr. Rosenzweig is the inaugural Director of the Institute for Heart and Brain Health (IHBH) at the University of Michigan Medical Center. Previous leadership roles include having served as Chief of Cardiology, Co-Director of the Corrigan Minehan Heart Center and Director of Cardiovascular Research at MGH, as well as the Paul Dudley White Professor of Medicine at Harvard Medical School (2015-2022). He also has served as the inaugural Director of the Program in Cardiovascular Gene Therapy at MGH, a Trustee of the Harvard Clinical Research Institute (an academic clinical research organization), an Executive Committee member of the Harvard Stem Cell Institute and its Cardiovascular Program Leader, as well as the Director of Cardiovascular Research and Associate Chief of Cardiology at the Beth Israel Deaconess Medical Center in Boston. Dr. Rosenzweig is also a member of the Leducq Foundation Scientific Advisory Committee and the American Heart Association Basic Sciences Council leadership. 


Dr. Rosenzweig’s research has focused on identifying novel mechanisms and therapeutic targets in heart failure, using the exercised heart to understand what keeps hearts healthy. Of particular interest is how dysregulation of common pathways, such as those involved in metabolism, cellular senescence, or inflammation, can drive disease in multiple organs, including the brain and heart since targeting such pathways could have broad clinical benefits. Dr. Rosenzweig is deeply committed to realizing the translational potential of basic science discoveries. His work has led to multiple patent awards, licensed approaches to mutation detection, and new therapeutic strategies being investigated in clinical trials. He has led successful partnerships with industry, served on industry advisory panels, and co-founded a recently funded biotech start-up focused on small molecule therapies for Long QT Syndrome. Dr. Rosenzweig has been a principal investigator for multiple successful research consortia, including an international Leducq Foundation Network of Research Excellence, multiple NIH U-awards, an AHA Strategically Focused Research Network Center, and multiple NIH T32 training grants. His research has been continuously funded by the NIH for over 30 years.


Dr. Rosenzweig is a devoted mentor to multiple students, residents, fellows, and junior faculty.  In his laboratory, he has personally supervised over sixty postdoctoral research fellows. Most former fellows have full-time academic faculty positions with substantial research commitments. Of note, fourteen hold major leadership positions including as Center Directors, Chairs and Chiefs of Departments and Divisions, and one is President of an international academic medical center. He has also served on the Scientific Board of the Sarnoff Foundation, an organization devoted to mentoring young investigators, and has mentored five Sarnoff fellows in his laboratory.


Previous awards and honors include the MGH Roman W. DeSanctis Clinical Scholar Award, election into the American Society for Clinical Investigation (ASCI), the American Association of Physicians (AAP), the Association of University Cardiologists (AUC), and the Association of Professors of Cardiology (APC), a MERIT Award from the American Heart Association and an Outstanding Investigator Award from the National Heart, Lung, and Blood Institute (NHLBI).